Compare Enveric Biosciences Inc (ENVB) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Shell PLC — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Shell PLC trades at $100.22 (market cap $284.34B). The key difference: Shell PLC is far larger — about 41814.7× Enveric Biosciences Inc's market cap, and Shell PLC pays a 3.12% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Shell PLC for 90 Days on average.
| ENVB | SHEL | |
|---|---|---|
Market Cap | $6.80M | $284.34B |
Volume | 64,867 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $10.80 | $100.20 |
52-Week Low | $1.27 | $70.31 |
Typical Hold Time | 14 Days | 90 Days |
Enterprise Value | -$1.49M | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Shell (SHEL) trades at $96.85, down 0.79% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company's valuation ratios are attractive, with a P/E of 11.08 and P/S of 0.97, while profitability metrics like a 14.35% ROE and 8.76% net margin reflect solid fundamentals. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, positioning Shell for long-term growth in energy transition markets.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, but risks involve volatile oil prices and execution challenges in new projects. The stock offers value with upside potential, though investors should monitor energy market dynamics and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
